Literature DB >> 16821268

Short-term gene expression changes in cartilage explants stimulated with interleukin beta plus glucosamine and chondroitin sulfate.

Pooi-See Chan1, John P Caron, Michael W Orth.   

Abstract

OBJECTIVE: To determine the short-term effects of glucosamine (GLN) and chondroitin sulfate (CS) on expression of genes encoding inflammatory mediators and matrix enzymes in bovine cartilage explants stimulated with interleukin 1 (IL-1).
METHODS: Dose-response experiments were conducted for IL-1, GLN, and CS to select concentrations of each optimized for detecting treatment effects on cartilage explants. Based on the dose-response experiments, treatments included fetal bovine serum (FBS) control, 15 ng/ml IL-1, and 15 ng/ml IL-1 with the addition of 10 microg/ml GLN and 20 microg/ml CS. Media were measured for nitric oxide (NO) and prostaglandin E2 (PGE2) while explants were frozen for RNA extraction at 8, 16, and 24 hours. Gene expression relative to FBS control for inducible NO synthase (iNOS), cyclooxygenase-2 (COX-2), microsomal PGE synthase-1 (mPGEs1), nuclear factor-kB p65 subunit (NF-kB), matrix metalloproteinase (MMP)-3 and 13, aggrecanase (Agg)-1 and 2, and tissue inhibitor of metalloproteinase-3 (TIMP-3) were assessed by quantitative real-time polymerase chain reaction (RT-PCR). In a separate study using incubation of explants with the same treatments for 48 hours, proteoglycan release was measured with dimethylmethylene blue assay and TIMP-3 protein was evaluated with Western blots.
RESULTS: The GLN and CS combination abrogated IL-1-induced gene expression of iNOS, COX-2, mPGEs1, and NF-kB at all timepoints. NO, PGE2, and proteoglycan release were reduced with the combination. The abundance of stimulated MMP-13, Agg-1, and Agg-2 mRNA was repressed, whereas TIMP-3 was upregulated by the combination at all timepoints. The abundance of TIMP-3 protein was increased by the combination relative to IL-1 at 48 hours.
CONCLUSION: GLN and CS in combination suppress synthesis and expression of genes encoding inflammatory mediators and proteolytic enzymes while upregulating TIMP-3. This provides a plausible mechanism for the purported mild antiinflammatory and chondroprotective properties of GLN and CS.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16821268

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  30 in total

1.  Use of glucosamine and chondroitin in relation to mortality.

Authors:  Griffith A Bell; Elizabeth D Kantor; Johanna W Lampe; Danny D Shen; Emily White
Journal:  Eur J Epidemiol       Date:  2012-07-25       Impact factor: 8.082

2.  Use of glucosamine and chondroitin and lung cancer risk in the VITamins And Lifestyle (VITAL) cohort.

Authors:  Theodore M Brasky; Johanna W Lampe; Christopher G Slatore; Emily White
Journal:  Cancer Causes Control       Date:  2011-06-25       Impact factor: 2.506

Review 3.  Effect of glucosamine and chondroitin sulfate in symptomatic knee osteoarthritis: a systematic review and meta-analysis of randomized placebo-controlled trials.

Authors:  Mario Simental-Mendía; Adriana Sánchez-García; Félix Vilchez-Cavazos; Carlos A Acosta-Olivo; Víctor M Peña-Martínez; Luis E Simental-Mendía
Journal:  Rheumatol Int       Date:  2018-06-11       Impact factor: 2.631

4.  Use of cartilage derived from murine induced pluripotent stem cells for osteoarthritis drug screening.

Authors:  Vincent P Willard; Brian O Diekman; Johannah Sanchez-Adams; Nicolas Christoforou; Kam W Leong; Farshid Guilak
Journal:  Arthritis Rheumatol       Date:  2014-11       Impact factor: 10.995

5.  Chondroitin sulfate in the treatment of osteoarthritis: from in vitro studies to clinical recommendations.

Authors:  Yves Henrotin; Mariane Mathy; Christelle Sanchez; Cecile Lambert
Journal:  Ther Adv Musculoskelet Dis       Date:  2010-12       Impact factor: 5.346

6.  Glucosamine supplementation demonstrates a negative effect on intervertebral disc matrix in an animal model of disc degeneration.

Authors:  Lloydine Jacobs; Nam Vo; Joao Paulo Coelho; Qing Dong; Bernard Bechara; Barrett Woods; Eric Hempen; Robert Hartman; Harry Preuss; Judith Balk; James Kang; Gwendolyn Sowa
Journal:  Spine (Phila Pa 1976)       Date:  2013-05-20       Impact factor: 3.468

7.  Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes.

Authors:  Valentina Calamia; Cristina Ruiz-Romero; Beatriz Rocha; Patricia Fernández-Puente; Jesús Mateos; Eulàlia Montell; Josep Vergés; Francisco J Blanco
Journal:  Arthritis Res Ther       Date:  2010-07-13       Impact factor: 5.156

8.  Effect of chondroitin sulphate in a rabbit model of atherosclerosis aggravated by chronic arthritis.

Authors:  G Herrero-Beaumont; M E Marcos; O Sánchez-Pernaute; R Granados; L Ortega; E Montell; J Vergés; J Egido; R Largo
Journal:  Br J Pharmacol       Date:  2008-04-21       Impact factor: 8.739

9.  Associations of herbal and specialty supplements with lung and colorectal cancer risk in the VITamins and Lifestyle study.

Authors:  Jessie A Satia; Alyson Littman; Christopher G Slatore; Joseph A Galanko; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-05       Impact factor: 4.254

10.  Specialty supplement use and biologic measures of oxidative stress and DNA damage.

Authors:  Elizabeth D Kantor; Cornelia M Ulrich; Robert W Owen; Peter Schmezer; Marian L Neuhouser; Johanna W Lampe; Ulrike Peters; Danny D Shen; Thomas L Vaughan; Emily White
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-08-05       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.